Okwenathi is a six-month-old baby at Tygerberg Children’s Hospital in Cape Town, South Africa. Since he was born, he has been fighting for his life against a series of bacterial infections. Tragically, a number of barriers prevent Okwenathi and other patients with serious bacterial infections around the world from being treated with the right antibiotics.

### BARRIERS TO ACCESS

Lack of access to antibiotics means loss of life. Many infections that could be treated with access to the right antibiotic become fatal. Nearly 1.3 million people die every year from antibiotic resistance.*

### ACCESS TO ANTIBIOTICS

Affordable in limited-resource settings. Available at the right time in the right place. Developed for use in children and adults. Used appropriately to minimize resistance.

### GARDP IS ADDRESSING ACCESS NOW

**Goal 1:** Advancing access to antibiotics in GARDP’s portfolio, both in development and after regulatory approval, including novel and generic antibiotics.

**Goal 2:** Securing access to a portfolio of novel and generic antibiotics via SECURE, a collaborative initiative developed by GARDP, WHO and other partners.

**Goal 3:** Improving the policy environment for access.

*Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis (2022), https://doi.org/10.1016/S0140-6736(21)02724-0*
EXPANDING ACCESS TO AN ANTIBIOTIC: CEFIDEROCOL

The cefiderocol access project aims to expand and accelerate global access to an antibiotic with the potential to treat serious infections caused by Gram-negative bacteria which may be resistant to other antibiotic treatments. GARDP has signed an innovative license agreement with the pharmaceutical company Shionogi & Co., Ltd., and a collaboration agreement with Shionogi and the Clinton Health Access Initiative (CHAI).

- Targets bacteria which have been labelled priority pathogens in urgent need of new treatments by the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC).
- Included on the WHO Model List of Essential Medicines.
- Covers 135 countries, including all low-income countries, most lower middle- and upper middle-income countries, and select high-income countries.
- Will forge new pathways for access to cefiderocol.
- Will generate new insights into how to sustainably introduce antibiotics for appropriate use in areas with limited access.
- Addresses antibiotic resistance that is harming people now.

THE ANTIBIOTIC

THE LICENSE AGREEMENT

THE PROJECT

Enable manufacturing of an affordable, quality-assured product from a licensed manufacturer.

Support registration and commercialization in countries with high burdens of resistant infections.

Develop and disseminate best practices and evidence for appropriate use of cefiderocol, in compliance with its label.

Work with partners to develop and implement product introduction plans.

#PowerofAntibiotics

GARDP.ORG

Help us accelerate access.

*For further information, please refer to the approved label.*